UBS upgraded Option Care Health (OPCH) to Buy from Neutral with a price target of $40, up from $38. The company’s Q1 results evidenced strong earnings momentum, despite a $5M impact from Stelara, which was more muted than anticipated given inventory management actions taken by Option, the analyst tells investors in a research note. The firm sees an attractive entry point at current share levels and continues to believe the company will see benefits from a secular shift in site of care from institutional to the home.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Option Care Health: Strong Growth Prospects and Strategic Market Position Justify Buy Rating
- Option Care Health Reports Strong Q1 2025 Results
- Option Care Health’s Earnings Call Highlights Strong Growth
- Option Care Health: Strong Financial Performance and Raised Guidance Justify Buy Rating